Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab and Lenalidomide as a Treatment for CAEBV：a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

NCT04518982 is registered in ClinicalTrials.gov with Zhao Wang as lead sponsor.

NCT NCT04518982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04518982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab and Lenalidomide as a Treatment for CAEBV：a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Lead sponsor
Zhao Wang
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2020
Completion date
August 1, 2021
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

caebv